Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades

References

• American Cancer Society. Cancer Facts & Figures 2022. 2022; Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html
   Google Scholar
• SEER Cancer Stat Facts: chronic Lymphocytic Leukemia. Bethesda MD: National Cancer Institute; Available from: https://seer.cancer.gov/statfacts/html/clyl.html
   Google Scholar
• Alrawashdh N, Sweasy J, Erstad B, McBride A, Persky DO, Abraham I. Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017). Ann Hematol. 2021;100(10):2501–2512. doi: 10.1007/s00277-021-04600-1
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111(10):4916–4921. doi: 10.1182/blood-2007-12-129379
   PubMed Web of Science ®Google Scholar
• Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager SM, Bowen DA, Conte M, Jelinek DF, Slager SL. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014;99(1):140–147. doi: 10.3324/haematol.2013.086066
   PubMed Web of Science ®Google Scholar
• Coombs CC, Falchi L, Weinberg JB, et al. Chronic lymphocytic leukemia in African Americans. Leukemia & Lymphoma. Leukemia Lymphoma. 2012;53(11):2326–2329. doi: 10.3109/10428194.2012.698276
   PubMed Web of Science ®Google Scholar
• Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa, MC, Strom S, Wierda WG, Ferrajoli A. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia. Cancer. 2013;119(17):3177–3185. doi: 10.1002/cncr.28030
   PubMed Web of Science ®Google Scholar
• Catovsky D, Wade R, Else M. The clinical significance of patients’ sex in chronic lymphocytic leukemia. Haematologica. 2014;99(6):1088–1094. doi: 10.3324/haematol.2013.101378
   PubMed Web of Science ®Google Scholar
• Number of Persons by Race and Hispanic Ethnicity for SEER Participants -. SEER Registries. https://seer.cancer.gov/registries/data.html
   Google Scholar
• Saad AM, Turk T, Al-Husseini MJ, et al. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018;18(1):688. doi: 10.1186/s12885-018-4610-4
   PubMed Web of Science ®Google Scholar
• Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–351. doi: 10.1002/(SICI)1097-0258(20000215)19:3<335:AID-SIM336>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Hansen MM. Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol Suppl. 1973;18:3–286.
   PubMedGoogle Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–234. Blood, 2016. 128(17): p. 2109. doi: 10.1182/blood.V46.2.219.219
   PubMed Web of Science ®Google Scholar
• Fu SM, Winchester RJ, Kunkel HG. Occurrence of surface IgM, IgD, and free light chains of human lymphocytes. J Exp Med. 1974;139(2):451–456. doi: 10.1084/jem.139.2.451
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Gobbi M, Bofill M, et al. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med. 1982;155(2):623–628. doi: 10.1084/jem.155.2.623
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916. doi: 10.1056/NEJM200012283432602
   PubMed Web of Science ®Google Scholar
• Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997;90(8):2863–2892. doi: 10.1182/blood.V90.8.2863
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps, TJ. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456. doi: 10.1182/blood-2007-06-093906
   PubMed Web of Science ®Google Scholar
• Yang S, Varghese AM, Sood N, et al. Ethnic and geographic diversity of chronic lymphocytic leukaemia. Leukemia. 2021;35(2):433–439. 10.1038/s41375-020-01057-5
   PubMed Web of Science ®Google Scholar
• Baumann Kreuziger LM, Tarchand G, Morrison VA. The impact of Agent Orange exposure on presentation and prognosis of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(1):63–66. doi: 10.3109/10428194.2013.794267
   PubMed Web of Science ®Google Scholar
• Casabonne D, Almeida J, Nieto WG, et al. Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults. Plos One. 2012;7(12):e52808. doi: 10.1371/journal.pone.0052808
   PubMed Web of Science ®Google Scholar
• Yao Y, Lin X, Li F, et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022;21(1):4. doi: 10.1186/s12938-021-00973-6
   PubMed Web of Science ®Google Scholar
• Rossi D, Gaidano G. The clinical implications of gene mutations in chronic lymphocytic leukaemia. Br J Cancer. 2016;114(8):849–854. doi: 10.1038/bjc.2016.78
   PubMed Web of Science ®Google Scholar
• Ilaria Del G, Robin F. Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia. Haematologica. 2019;104(2):219–221. doi: 10.3324/haematol.2018.207399
   PubMed Web of Science ®Google Scholar
• Zhu Q, Tan D, Samuel M, et al. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leukemia Lymphoma. 2004;45(11):2239–2245. doi: 10.1080/10428190412331283260
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM, Busch R, Maye J, Hensel, M, Hopfinger G, Hess G, von Gruenhagen, U, Bergmann MA, Catalano J. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). Blood. 2008;112(11):325.
   Web of Science ®Google Scholar
• Eichhorst B, Fink A-M, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–942. doi: 10.1016/S1470-2045(16)30051-1
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110. 10.1056/NEJMoa1313984
   PubMed Web of Science ®Google Scholar
• O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–1418. 10.1016/S1470-2045(16)30212-1
   PubMed Web of Science ®Google Scholar
• Montserrat E, Gomis F, Vallespí T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood. 1991;78(6):1545–1551. doi: 10.1182/blood.V78.6.1545.1545
   PubMed Web of Science ®Google Scholar
• Dhodapkar M, Tefferi A, Su J, et al. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study. Leukemia. 1993;7(8):1232–1235.
   PubMed Web of Science ®Google Scholar
• Daniel C, Rachel W, Monica E. The clinical significance of patients’ sex in chronic lymphocytic leukemia. Haematologica. 2014;99(6):1088–1094. doi: 10.3324/haematol.2013.101378
   PubMed Web of Science ®Google Scholar
• Nabhan C, Aschebrook-Kilfoy B, Evens AM, Chiu BC, Smith SM, Shanafelt TD, Kay NE. The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras. Blood. 2012;120(21):2877. doi:10.1182/blood.V120.21.2877.2877
   Web of Science ®Google Scholar
• Yu JB, Gross CP, Wilson LD, et al. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park). 2009;23(3):288–295.
   PubMed Web of Science ®Google Scholar